Esperion Therapeutics (ESPR) Free Cash Flow (2012 - 2026)

Esperion Therapeutics has reported Free Cash Flow for 15 years, with the latest figure at -$27.9 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 23.35% year-over-year to -$27.9 million; the trailing twelve-month figure through Mar 2026 stood at -$18.6 million (up 81.42% YoY), and the FY2025 full-year result was -$13.3 million, up 43.85% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$27.9 million, down from $45.1 million in the prior quarter.
• The five-year high for Free Cash Flow was $53.6 million in Q1 2024, with the low at -$54.4 million in Q1 2023.
• Historically, Free Cash Flow has averaged -$22.1 million across 5 years, with a median of -$31.4 million in 2025.
• The largest YoY upside for Free Cash Flow was 230.08% in 2025 against a maximum downside of 338.85% in 2025.
• Esperion Therapeutics' Free Cash Flow stood at -$42.5 million in 2022, then increased by 12.75% to -$37.1 million in 2023, then increased by 6.53% to -$34.6 million in 2024, then soared by 230.08% to $45.1 million in 2025, then tumbled by 161.95% to -$27.9 million in 2026.
• The last three Free Cash Flow figures came in at -$27.9 million (Q1 2026), $45.1 million (Q4 2025), and -$4.3 million (Q3 2025), per Business Quant data.